Companies say nearly 200 possibilities available through combined services.

PerkinElmer and Cerep say that more than 200 kinase assays are now available thanks to use of PerkinElmer’s LanceUltra technology to validate new products in Cerep’s drug candidate selections and qualifications services.

The collaboration, which began last April, combines PerkinElmer’s assay technologies and Cerep’s target screening and drug discovery offerings in therapeutic research pathways such as cancer, central nervous system disorders, cardiac disease, inflammation, diabetes, and other metabolic disorders, say the companies.

“The extensive range of high quality kinase assays now available for screening and profiling through this collaboration is a compelling complement to the profiling services offered by Cerep,” says Richard M. Eglen, Ph. D., president, Biodiscovery, PerkinElmer. “It provides our customers with the expansive range of products and expertise necessary for broad compound screening campaigns to aid their research.”

The companies say that the drug discovery process is now simplified by offering the ability to complete a drug discovery process with PerkinElmer using only one vendor. Cerep customers have access to the fruits of PerkinElmer’s Bio-Discovery wing, including screening and assays such as radioligand binding assays for G protein-coupled receptor and kinase assay development.ADNFCR-2184-ID-19143240-ADNFCR

Previous articleSwine Flu fear Boosts Biotech Stocks
Next articleDuke University to Use WaferGen’s Real-Time PCR System to Validate Cancer SNPs